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Abstract The MDM2 oncoprotein is a negative regulatory
partner of the p53 tumour suppressor. MDM2 mediates
ubiquitination of p53 and targets the protein to the cytoplasm
for 26S proteosome-dependent degradation. In this paper, we
show that MDM2 is modified in cultured cells by multisite
phosphorylation. Deletion analysis of MDM2 indicated that the
sites of modification fall into two clusters which map respectively
within the N-terminal region encompassing the p53 binding
domain and nuclear export sequence, and the central acidic
domain that mediates p14ARF binding, p53 ubiquitination
and cytoplasmic shuttling. The data are consistent with
potential regulation of MDM2 function by multisite
phosphorylation. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
p53 is a latent and highly labile transcription factor which is
activated by, and is an integration point for, a wide range of
cellular stresses including DNA damage, activated oncogenes
and hypoxia (for reviews, see [1^6]). In response to an induc-
ing signal, p53 accumulates in the nucleus and coordinates a
change in the balance of gene expression leading to growth
arrest or apoptosis, events which prevent the growth or sur-
vival of damaged cells. At present, there are more than 100
genes known to be directly activated by p53, many of which
promote growth arrest or apoptosis [7].
Signals arising from cellular stress initiate a complex series
of regulatory events in the p53 pathway leading to increased
stability of p53 and activation of its biochemical functions [1^
3,5]. These signals converge at the interaction of p53 with its
negative regulatory partner, MDM2 (reviewed in [1,8]). The
binding of MDM2 to the N-terminus of p53 (amino acids 19^
26) represses p53 transcriptional activity [9,10], mediates ubiq-
uitination of p53 by acting as an E3 ligase [11,12] and targets
p53 to the cytoplasm for 26S proteosome-dependent degrada-
tion [13^16]. The mdm2 gene is itself activated by p53 and the
two proteins therefore form an autoregulatory loop in which
p53 positively regulates MDM2 expression while MDM2 neg-
atively regulates p53 levels and activity [17]. The N-terminal
102 amino acids of MDM2 are responsible for binding to the
N-terminus of p53 while regions within both the central acidic
domain and C-terminus of MDM2 are required for targeting
p53 to the proteosome [18].
Disruption of the p53^MDM2 complex is a pivotal event
during the induction of p53 and is su⁄cient to invoke p53-
mediated gene expression and cell cycle arrest [19]. The mech-
anism(s) by which this occurs physiologically is still unclear
and recent e¡orts have been focussed intensely on understand-
ing the role of multisite phosphorylation and acetylation of
p53 in this process (reviewed in [1^3,5]). However, while p53
modi¢cations may contribute to weakening the p53^MDM2
interaction, others have shown that phosphorylation of p53 is
not su⁄cient for stabilisation induced by DNA damage or by
dominant oncogenes [20^23]. These ¢ndings suggest that the
MDM2 protein itself may be the principal target of signals
which stabilise p53. In support of this idea, DNA damage-
induced phosphorylation of MDM2 in vivo has recently been
inferred on the basis of phosphatase-sensitive changes in the
electrophoretic mobility of MDM2 in irradiated or NCS-
treated cells [22]. This modi¢cation(s) is likely to be mediated
by the ATM protein kinase, but the site(s) of modi¢cation has
not yet been identi¢ed [22]. Moreover, although other reports
indicate that cellular MDM2 is a phosphoprotein [24], and is
an in vitro substrate for other protein kinases including DNA-
activated protein kinase [25] and protein kinase CK2 [26,27],
the full extent of MDM2 phosphorylation is not known nor is
the role of MDM2 post-translational modi¢cation in control-
ling the p53^MDM2 interaction understood.
In this paper, we have used chymotryptic phosphopeptide
mapping to analyse the phosphorylation of MDM2 in cell
lines. The data reveal the multisite nature of MDM2 phos-
phorylation and localise two clusters of phosphorylation sites
to two important functional regions of MDM2, the p53 bind-
ing domain and the ubiquitination/p53 degradation domain.
These data provide a basis for the identi¢cation of regulatory
modi¢cations which may mediate MDM2 function in re-
sponse to stress signals.
2. Materials and methods
2.1. Plasmids
Wild type murine MDM2 cDNA was cloned into the mammalian
expression vector pcDNA3 (Invitrogen). A DNA fragment encoding
four contiguous copies of the c-Myc 9E10 epitope (human c-Myc
amino acids 408^439 [28]) was cloned immediately at either the 5P
or 3P ends of the MDM2 coding sequence. Deletion derivatives were
generated using oligonucleotide-directed mutagenesis which substi-
tuted speci¢c codons with stop codons. These plasmids are all listed
in Table 1.
2.2. Cell lines and transfections
MCF-7, HeLa, SAOS-2 and COS-7 cells were maintained in Dul-
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becco^Vogt modi¢ed Eagle’s medium (DMEM: Gibco BRL) supple-
mented with 10% foetal bovine serum (Gibco BRL), 100 Wg/ml Pen/
strep (Gibco BRL) and 2 mM glutamine (Gibco BRL). The cells were
incubated at 37‡C in a humidi¢ed 5% carbon dioxide atmosphere.
For transfection, 10 cm plates were seeded with 5U105 cells in
normal growth medium and incubated at 37‡C for 24 h. Transfection
of cells (8 Wg of plasmid DNA per plate) was carried out using Lipo-
fectamine reagent according to the manufacturer’s instructions (Gibco
BRL). The cells were then incubated at 37‡C for 5 h before replacing
the transfection reagent with complete growth medium. The following
day, cells were washed three times with normal medium and main-
tained in this medium for a further 24 h, prior to preparation for
[32P]orthophosphate labelling.
2.3. Radiolabelling of cells with [32P]orthophosphate and
immunoprecipitation
Cells were pre-incubated with 8 ml of phosphate-free DMEM (Sig-
ma) containing 10% dialysed foetal calf serum at 37‡C for 1 h. The
medium was replaced with the same volume containing 4 mCi of
[32P]orthophosphate per plate and incubated at 37‡C for a further
3 h. After labelling, the cells were washed twice with 5 ml ice cold
phosphate-bu¡ered saline (PBS) and lysed in 1 ml of ice cold NP-40
bu¡er (10 mM NaH2PO4, 2 mM EDTA, 0.1 M NaCl, 1% NP-40 and
1 mM benzamidine). The samples were centrifuged at 13 000 rpm for
10 min and the supernatant fraction was collected. Immunoprecipita-
tion of the Myc-tagged MDM2 from the lysates was performed over-
night at 4‡C on an Eppendorf wheel with 75 Wl of protein A-Sephar-
ose and 2^5 Wg of 9E10 antibody [28]. The protein A-Sepharose 4B
beads were subsequently washed three times, each with 1 ml ice cold
RIPA bu¡er (10 mM NaH2PO4, 2 mM EDTA, 0.1 M NaCl, 1% NP-
40, 1 mM benzamidine, 1% sodium deoxycholate and 0.1% sodium
dodecyl sulfate (SDS)) and once with 1 ml of ice cold 50 mM Tris pH
7.5. 25 Wl of 2USDS sample bu¡er was added and the samples were
heat-denatured then separated on 10% SDS gels.
2.4. Chymotryptic phosphopeptide mapping
Two-dimensional thin layer phosphopeptide analysis of MDM2 was
carried out using essentially the same procedure as has been used
previously for p53 [29] with two exceptions: (i) chymotrypsin was
used to digest the protein in place of trypsin and (ii) the solvent
used for the chromatographic separation comprised isobutyric acid
(62.5%, v/v), n-butanol (1.9%, v/v), pyridine (4.8%, v/v) and glacial
acetic acid (2.9%, v/v) in deionised water.
2.5. Western analysis
Proteins were transferred to Immobilon-P membranes (Millipore)
using a Millipore SDE dry-blotting apparatus. The membranes were
probed with the c-Myc 9E10 monoclonal antibody at 1 Wg/ml in 5%
(w/v) skimmed milk powder (Marvel) and 0.05% (v/v) Tween 20 in
PBS. Detection was carried out using horseradish peroxidase-conju-
gated anti-mouse IgG (Scottish Antibody Production Unit), followed
by chemiluminescence detection (ECL, Amersham).
3. Results
Labelling of established cells lines with [32P]orthophosphate
followed by immunoprecipitation of MDM2, SDS^PAGE
and autoradiography produced only very weak signals with
insu⁄cient radiolabelled material to permit unequivocal phos-
phopeptide analysis (data not shown). Therefore, in order to
analyse the phosphorylation of MDM2 in cultured cells, we
expressed the murine MDM2 protein ectopically in a range of
cell lines using a pcDNA3-based vector in which the MDM2
proteins are tagged either at the N- or C-termini with the Myc
9E10 epitope [28]. These plasmids directed expression of the
MDM2 proteins in a range of cell lines. Representative data
shown in Fig. 1A indicate that the transiently expressed pro-
teins were clearly detectable in extracts of transfected COS-7
and MCF-7 cells using the 9E10 monoclonal antibody (ex-
pression was also detected in SAOS-2 and HeLa cells,
although at a signi¢cantly lower level (data not shown)).
COS-7 and MCF-7 cells transiently expressing N-terminally
Myc-tagged MDM2 were also labelled with [32P]ortho-
phosphate and the recombinant MDM2 proteins were im-
munoprecipitated from the labelled extracts. Two-dimensional
chymotryptic phosphopeptide analysis of these proteins re-
vealed that in each case multiple phosphopeptides were
present in MDM2 (Fig. 1B) consistent with the occurrence
of multisite phosphorylation of MDM2 in vivo. Comparison
of the maps from the COS-7 and MCF-7 cells indicated that
the phosphopeptide patterns were strikingly similar, although
there were some minor quantitative di¡erences. These data
Table 1
MDM2 mammalian expression plasmids
Plasmid number MDM2 status Myc 9E10 epitope
pDWM487 full length wild type not tagged
pDWM659 full length wild type tag at N-terminus
pDWM667 stop at codon 194 (v1) tag at N-terminus
pDWM668 stop at codon 294 (v2) tag at N-terminus
pDWM669 stop at codon 370 (v3) tag at N-terminus
pDWM794 full length wild type tag at C-terminus
Fig. 1. Expression and chymotryptic phosphopeptide analysis of re-
combinant murine MDM2 in various cell lines. (A) The pcDNA3-
derived plasmids pDWM487 (expressing untagged murine MDM2),
pDWM659 and pDWM794 (expressing murine MDM2 tagged with
the Myc 9E10 epitope at the N- or C-terminus, respectively) were
transfected into di¡erent cell lines. 48 h post-transfection, extracts
were made and expression of the recombinant MDM2 proteins was
determined by Western analysis using the Myc 9E10 monoclonal
antibody as probe. The panels are: (i) expression of untagged, N-
terminally Myc-tagged MDM2, and C-terminally Myc-tagged
MDM2 in COS-7 cells, (ii) expression of N-terminally Myc-tagged
MDM2 in COS-7 and MCF-7 cells. In all cases Con refers to cells
transfected with the empty pcDNA3 vector. (B) COS-7 or MCF-7
cells transiently expressing N-terminally Myc-tagged MDM2 were
pulse-labelled with [32P]orthophosphate. Extracts were prepared and
the recombinant MDM2 proteins were immunoprecipitated using
the 9E10 monoclonal antibody and analysed by chymotryptic phos-
phopeptide mapping. Representative maps from the COS-7 (i) and
MCF-7 (ii) cells are shown. The origins at which the peptides were
loaded are indicated by arrowheads.
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indicated that the modi¢cations on the MDM2 protein were
not cell type-dependent.
In order to explore the localisation of these modi¢cations,
the phosphorylation status of full length MDM2 was analysed
in comparison with three C-terminally truncated MDM2 mu-
tants (v1^3; these mutants are described in Fig. 2A and Table
1). Immunoprecipitation of the 32P-labelled MDM2 from
transiently transfected COS-7 cells followed by SDS^PAGE
revealed that, as with full length MDM2, each of the trun-
cated proteins was phosphorylated in vivo (Fig. 2B). The v1
protein, however, showed a considerably reduced level of
phosphorylation, suggesting that this protein lacked sites of
phosphorylation (parallel Western analysis indicated that the
levels of expression of the wild type and deletion mutant pro-
teins were similar (data not shown)). Chymotryptic phospho-
peptide analysis of these proteins highlighted di¡erences in the
modi¢cation status of the proteins (Fig. 2B (i^iv)). A major
phosphopeptide in the full length MDM2 protein (indicated in
(i) by an open arrow) was absent or very weak in the v3
mutant (ii), suggesting that there is a phosphorylation site(s)
C-terminal to amino acid 369. An alternative explanation,
however, would be that sequences in the 369^491 region are
required to permit e⁄cient phosphorylation of a site encom-
passed within the region encoded by the v3 mutant. At
present, we cannot distinguish between these alternatives.
All of the other major phosphopeptides resemble those ob-
served in the full length protein, consistent with the idea that
most of the phosphorylation sites lie between residues 1 and
369. Analysis of the v2 mutant (iii) narrowed down the loca-
tion of these sites to within amino acids 1^293. However, two
additional phosphopeptides appeared suggesting the possibil-
ity that this deletion had revealed cryptic (and possibly un-
physiological) sites (indicated by the open arrows). Strikingly,
the v1 mutant completely lacked the dense group of phospho-
peptides on the left-hand-side of the map (indicated by the
double-ended open arrow). These data suggest strongly that
this group of peptides is located within amino acids 194^293.
This is an important region of the MDM2 protein which is
required for nucleo-cytoplasmic shuttling, ARF binding and
ubiquitination of p53 [30,31]. Additionally, the v1 mapping
data assign the remaining group of phosphopeptides to resi-
dues 1^193. Once again, these lie in a key functional region
which encompasses the p53 binding domain (amino acids 23^
108), the nuclear localisation sequence (176^182) and the nu-
clear export sequence (184^195). Interestingly, the v1 map
shows the appearance of a novel, relatively hydrophobic phos-
phopeptide not present in the larger MDM2 proteins (indi-
cated with an open arrow in (iv)). We believe that this phos-
phopeptide most likely arises from phosphorylation of serine
189 (which lies within the NES) for two reasons: (a) chymo-
tryptic cleavage of the v1 protein on the C-terminal side of
Phe-186 would produce a small negatively charged peptide
with migrational properties (calculated according to [32]) sim-
ilar to the novel peptide in (iv); and (b) this small phospho-
peptide would never be observed in either the full length, v2
or v3 proteins because it would be part of a large 56 amino
Fig. 2. 32P-labelling and chymotryptic phosphopeptide analysis of full length recombinant murine MDM2 and various C-terminally truncated
MDM2 mutants in COS-7 cells. (A) Schematic representation of MDM2 showing key functional domains and the C-terminally truncated mu-
tants v1^3. The numbers refer to amino acid positions. (B) COS-7 cells transiently expressing N-terminally Myc-tagged MDM2 proteins (full
length MDM2 and v1^3) were pulse-labelled with [32P]orthophosphate. Extracts were prepared and the recombinant MDM2 proteins were im-
munoprecipitated using the 9E10 monoclonal antibody, resolved by SDS^PAGE and visualised by autoradiography. (C) The radiolabelled pro-
teins in B were further analysed by chymotryptic phosphopeptide mapping. The origins at which the peptides were loaded are indicated by ar-
rowheads. Points of interest in each of the panels, discussed in the text, are indicated by the broad open arrows.
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acid peptide (187^243) which would have restricted mobility
in the two-dimensional system and which is likely to contain
additional sites of phosphorylation (unpublished data). How-
ever, although this is highly suggestive of phosphorylation
within the NES, the alternative explanation, that the deletion
may unmask a cryptic phosphorylation site, cannot be ruled
out.
4. Discussion
There are three important conclusions which arise from the
present study. Firstly, the data indicate that the MDM2 on-
coprotein is modi¢ed by multisite phosphorylation in cultured
cells. These data are consistent with multiple signalling path-
ways impinging on MDM2 and raise the possibility that p53
and MDM2 may be targeted in a coordinate manner by over-
lapping signal transduction mechanisms. The second point is
that MDM2 phosphorylation patterns are similar in di¡erent
cell lines (Fig. 1), indicating that the modi¢cations are un-
likely to be an artefactual consequence of using a particular
cell line. The third conclusion is that the majority of the
phosphopeptides arise from phosphorylation of MDM2 with-
in two distinct important functional domains, the region re-
sponsible for p53 binding, and the central acidic region which
mediates nucleo-cytoplasmic shuttling, ARF binding and
ubiquitination of p53. The data suggest that the activities
encompassed within these regions of MDM2 are likely to be
under tight, and possibly independent, control through post-
translational modi¢cation.
From a technical standpoint, the study o¡ers a number of
advantages. For example, the use of chymotrypsin to generate
phosphopeptides, combined with the conditions of electropho-
retic and chromatographic separation employed, permit very
e¡ective resolution of the phosphopeptides in two dimensions.
One previous study has examined MDM2-derived phospho-
peptides generated by digestion with trypsin followed by pro-
nase [24]. Our own analyses using trypsin to digest phosphor-
ylated MDM2 gave only very poor resolution of the peptides
(data not shown) and this may be one reason why Deppert
and co-workers employed a double digestion system [24]. We
also believe that the use of chymotrypsin, which o¡ers the
advantage of speci¢city in determining sites of digestion which
the use of pronase lacks, underscores the multisite nature of
the phosphorylation of MDM2 (i.e. by eliminating the possi-
bility of multiple peptides containing a single or few phos-
phorylation sites being generated through random partial
cleavage). One caveat to the approach we have adopted is
that we have analysed MDM2 molecules which are tagged
and over-expressed. However, while we acknowledge that
there is a slight possibility that tagging or over-expression
may in£uence the phosphorylation status of the recombinant
MDM2, the approach we have developed has not only over-
come technical di⁄culties which are encountered from the
analysis of endogenous MDM2 using currently available
MDM2 antibodies (data not shown), but provides a powerful
approach for further detailed analysis of MDM2 multisite
phosphorylation, particularly when used in conjunction with
other methods such as deletion or mutational analysis. Ac-
cordingly, this approach will be of considerable bene¢t in
identifying residues phosphorylated in vivo (for example, by
the use of site-directed mutagenesis of target residues) and in
vitro by candidate protein kinases. Once the sites of modi¢-
cation have been rigorously identi¢ed, it will then be possible
to generate phospho-speci¢c antibodies which can discrimi-
nate between MDM2 molecules that are phosphorylated and
those that are not phosphorylated at potential regulatory
sites, on an individual basis. The availability of such reagents
will be pivotal in discerning the induction and kinetics of these
key modi¢cations on endogenous MDM2 in response to a
range of cellular stresses.
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